Interferon-α
1
Reactions 937 - 8 Feb 2003 S Interferon-α Autoimmune hepatitis: case report A 47-year-old man developed autoimmune hepatitis while receiving interferon-α for chronic myeloid leukaemia. The man had been receiving SC interferon-α [‘Roferon-A’] 8MU once daily for 5 months when liver enzyme elevation was noted; he had received concomitant hydroxycarbamide [hydroxyurea] during the first 3 months of interferon-α therapy. Interferon-α-induced hepatitis was considered and his dose was gradually reduced from 8 to 4 MU/day without improvement. Interferon-α was then discontinued approximately 7 months after liver enzyme elevation was noted. His liver enzyme levels subsequently showed a dramatic rise with AST and alkaline phosphatase levels of 1176 and 319 U/L, respectively, and a bilirubin level of 37 µmol/L. Liver histopathology revealed excess eosinophilic and portal inflammatory infiltrate and was consistent with autoimmune hepatitis. The man received a tapering course of prednisone during which hydroxycarbamide was restarted. A repeat liver biopsy was consistent with chronic hepatitis so his prednisone dose was increased. Liver function tests at this time showed AST and alkaline phosphatase levels of 110 and 129 U/L, respectively, and a bilirubin level of 8 µmol/L. His prednisone dose was subsequently retapered and his liver function tests returned to normal. Al Ashgar H, et al. Autoimmune hepatitis induced by interferon-alpha therapy in a patient with chronic myeloid leukemia. Annals of Saudi Medicine 22: 73-74, Jan- Mar 2002 - Saudi Arabia 807210699 1 Reactions 8 Feb 2003 No. 937 0114-9954/10/0937-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Interferon-α
Reactions 937 - 8 Feb 2003
SInterferon-αAutoimmune hepatitis: case report
A 47-year-old man developed autoimmune hepatitis whilereceiving interferon-α for chronic myeloid leukaemia.
The man had been receiving SC interferon-α [‘Roferon-A’]8MU once daily for 5 months when liver enzyme elevation wasnoted; he had received concomitant hydroxycarbamide[hydroxyurea] during the first 3 months of interferon-αtherapy. Interferon-α-induced hepatitis was considered andhis dose was gradually reduced from 8 to 4 MU/day withoutimprovement. Interferon-α was then discontinuedapproximately 7 months after liver enzyme elevation wasnoted. His liver enzyme levels subsequently showed adramatic rise with AST and alkaline phosphatase levels of 1176and 319 U/L, respectively, and a bilirubin level of 37 µmol/L.Liver histopathology revealed excess eosinophilic and portalinflammatory infiltrate and was consistent with autoimmunehepatitis.
The man received a tapering course of prednisone duringwhich hydroxycarbamide was restarted. A repeat liver biopsywas consistent with chronic hepatitis so his prednisone dosewas increased. Liver function tests at this time showed AST andalkaline phosphatase levels of 110 and 129 U/L, respectively,and a bilirubin level of 8 µmol/L. His prednisone dose wassubsequently retapered and his liver function tests returned tonormal.Al Ashgar H, et al. Autoimmune hepatitis induced by interferon-alpha therapy in apatient with chronic myeloid leukemia. Annals of Saudi Medicine 22: 73-74, Jan-Mar 2002 - Saudi Arabia 807210699
1
Reactions 8 Feb 2003 No. 9370114-9954/10/0937-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
